BPC-157 & the Peptide-Clinic Market
BPC-157, The Unapproved 'Healing Peptide'
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved; restricted from 503A compounding (Category 2, 2023)
Reference only. Not medical advice.
What can go wrong
Because there are no controlled human safety data, the true risk profile is unknown. Practical risks are dominated by sourcing: most BPC-157 is gray-market 'research' material of unverified purity, potency, and sterility, with documented potential for contamination and mislabeling. The FDA's immunogenicity concern means an unknown risk of immune reactions.
This is something to take to a clinician. The Atlas can tell you what is known about bpc-157 & the peptide-clinic market in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
BPC-157 ('Body Protection Compound-157') is a synthetic 15-amino-acid peptide derived from a sequence in gastric juice, marketed for tendon/ligament/gut healing and recovery. It has no FDA approval and essentially no controlled human trial data; the evidence base is preclinical (rodent) work. In 2023 the FDA placed BPC-157 in Category 2 of its interim 503A bulk-substance guidance, effectively blocking compounding pharmacies from using it, citing immunogenicity, impurity, and safety-data concerns. It is a centerpiece of the gray-market peptide economy.
The internet's favorite recovery peptide, and a regulatory flashpoint.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Proposed mechanisms from animal studies include promotion of angiogenesis, modulation of nitric oxide pathways, and effects on growth-factor signaling and tendon fibroblast outgrowth. These mechanisms are not validated in humans, and the leap from rodent injury models to human therapeutic benefit is unestablished.
Preclinical does not mean proven
Nearly all of the enthusiastic mechanism literature is from animal models. There are no robust randomized human trials demonstrating efficacy or characterizing long-term safety. The FDA's stated concerns, immunogenicity, peptide-related impurities, and lack of human safety data, are precisely the gaps that the marketing glosses over.
Safety in detail
BPC-157 is not FDA-approved and was restricted from compounding in 2023. Human safety is uncharacterized, and gray-market product carries documented contamination and purity risks. Self-administration is not medically supervised use.
What people get wrong
Often saidBPC-157 is a clinically proven healing peptide
ActuallyThere are essentially no controlled human trials. Efficacy claims rest on animal studies.
Often saidIt is legal and FDA-cleared because clinics sell it
ActuallyIt is not FDA-approved, and in 2023 the FDA restricted it from compounding (Category 2). Most supply is gray-market 'research chemical.'
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Type
- Synthetic pentadecapeptide
- Human RCTs
- None of note
- FDA approval
- None
- 2023 FDA action
- Placed in Category 2 (restricted from 503A compounding)
- Primary evidence
- Rodent / preclinical
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about BPC-157 & the Peptide-Clinic Market. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Preclinical literature/patent reviews2025
Multiple reviews catalog rodent tendon/gut healing signals; authors note absence of definitive human evidence